Document Detail


First human experience with angiopeptin-eluting stent: a quantitative coronary angiography and three-dimensional intravascular ultrasound study.
MedLine Citation:
PMID:  16208695     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Angiopeptin has been shown to reduce in-stent restenosis in various animal models. Meanwhile, BiodivYsio DD phosphorylcholine (PC)-coated stent provides a platform for local delivery of antiproliferative agents to the coronary artery. We studied the feasibility, safety, and impact on tissue growth of angiopeptin-eluting BiodivYsio DD PC-coated stents in human native de novo coronary lesions. We enrolled 14 patients (16 lesions) who underwent intravascular ultrasound (IVUS)-guided angiopeptin-eluting stent implantation in native coronary arteries between 3.0 and 4.0 mm in diameter with lesion length<or=18 mm. We successfully implanted 13 stents loaded with 22 microg of angiopeptin and three stents with 126 microg of angiopeptin. No major adverse cardiac events or target vessel failure occurred at 1-year clinical follow-up. All patients underwent 6-month angiographic and volumetric IVUS follow-up. In-stent late loss was 0.46+/-0.32 mm in the low-dose group and 0.26+/-0.14 mm in the high-dose group. Binary restenosis rate was 0%. Follow-up percentage neointimal hyperplasia by IVUS was 18.4%+/-22.5% for the low-dose group and 10.2%+/-5.8% for the high-dose group, respectively. There were no edge effect and late stent malapposition. Angiopeptin-eluting BiodivYsio DD PC stent appears feasible and safe in treating native de novo coronary lesions with modest degree of neointimal hyperplasia.
Authors:
On-Hing Kwok; Wing-Hing Chow; Tin-Chu Law; Alex Chiu; William Ng; Wai-Fat Lam; Mun K Hong; Jeffrey J Popma
Related Documents :
8869025 - Intravascular ultrasound: a guide for management of complications during intervention?
8806335 - Quantification of the minimal luminal cross-sectional area after coronary stenting by t...
10556405 - The erasme study: a multicenter study on the safety and technical results of the palmaz...
12508205 - Carotid brachytherapy for in-stent restenosis.
16678575 - Integrated coronary revascularization with drug-eluting stents: immediate and seven-mon...
9758385 - Bifid left atrial appendage with thrombus: source of thromboembolism.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions     Volume:  66     ISSN:  1522-1946     ISO Abbreviation:  Catheter Cardiovasc Interv     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-11-28     Completed Date:  2006-04-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100884139     Medline TA:  Catheter Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  541-6     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2005 Wiley-Liss, Inc.
Affiliation:
Division of Cardiology, Grantham Hospital, Hong Kong, and Division of Cardiology, Weill Cornell Medical College, New York, NY, USA. vohkwok@hksh.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Vessel Prosthesis Implantation / instrumentation*
Cardiovascular Agents / pharmacology
Coated Materials, Biocompatible*
Coronary Angiography*
Coronary Stenosis / radiography,  surgery*,  ultrasonography
Feasibility Studies
Female
Follow-Up Studies
Humans
Male
Middle Aged
Oligopeptides / pharmacology*
Prospective Studies
Somatostatin / analogs & derivatives*,  pharmacology
Stents*
Treatment Outcome
Ultrasonography, Interventional / methods*
Chemical
Reg. No./Substance:
0/Cardiovascular Agents; 0/Coated Materials, Biocompatible; 0/Oligopeptides; 113294-82-9/angiopeptin; 51110-01-1/Somatostatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical features of 78 adults with 22q11 Deletion Syndrome.
Next Document:  First report on a human percutaneous transluminal implantation of a self-expanding valve prosthesis ...